The clinical effect of TS-1 in advanced and recurrent gastric cancer with peritoneal dissemination
Inaba, Y.; Watabe, S.; Ohe, S.; Kamio, Y.; Koyama, M.; Hayashi, K.-i.; Chiba, M.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 29(2): 239-244
2002
ISSN/ISBN: 0385-0684 PMID: 11865630 Document Number: 550846
Eighteen patients with far advanced and recurrent gastric cancer with peritoneal dissemination were treated with a novel oral anticancer drug, TS-1, and assessed according to clinical effect. TS-1 was administered at a dose of 80-120 mg/day. One course consisted of consecutive administration of TS-1 for 28 days followed by 14 days rest. The 1- and 2-year survival rates and median survival time after administration of TS-1 were 63.2%, 23.7% and 437 days, respectively. Eight patients (44.4%) survived for 1 year or more. Adverse reactions consisted of reduction in hemoglobin level and hyperbilirubinemia at grades 3 and 4, which were observed in 3 patients and 1 patient, respectively. TS-1 is a promising drug for gastric cancer with peritoneal dissemination.